Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults

Trial Profile

Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Rabies vaccine (Primary)
  • Indications Rabies
  • Focus Adverse reactions
  • Sponsors CureVac
  • Most Recent Events

    • 28 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Oct 2016.
    • 28 Jul 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Aug 2016.
    • 01 Dec 2015 Status changed from recruiting to active, no longer recruiting as per Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top